- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Combination Product
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1729–1752
of 13,084
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 39
- States / cities
- Berkeley, California • Duarte, California • La Jolla, California + 30 more
- Conditions
- Diarrhea
- Interventions
- Sodium dichloroisocyanurate (NaDCC) tablets, Placebo
- Other
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- Not listed
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
- Interventions
- Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 739 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2033
- U.S. locations
- 709
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
- Conditions
- Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Urbana, Illinois • St Louis, Missouri + 4 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
- Device
- Lead sponsor
- Cervel Neurotech, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Lebanon, New Hampshire + 3 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Levalbuterol HCl, Albuterol Sulfate, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 35 Years to 99 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 20
- States / cities
- Carmichael, California • Spring Valley, California • Wheat Ridge, Colorado + 17 more
- Conditions
- Breast Cancer
- Interventions
- Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- Female only
- Enrollment
- 2,411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2010
- U.S. locations
- 134
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more
- Conditions
- Bronchopulmonary Dysplasia (BPD)
- Interventions
- CPAP, Nasal Cannula
- Device
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 31 Weeks
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2011
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Endocrine Therapy (ET)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
- Interventions
- Dapagliflozin 10 mg, Placebo tablet
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 17,190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 234
- States / cities
- Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
- Conditions
- Bradycardia, Tachycardia, Heart Disease
- Interventions
- Cardiac Rhythm Management device
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,957 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 80
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 72 more
- Conditions
- Diabetes
- Interventions
- Placebo, TAK-875
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 78 more
- Conditions
- Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
- Interventions
- CNP-103, Placebo
- Drug
- Lead sponsor
- COUR Pharmaceutical Development Company, Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 45
- States / cities
- Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 171
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
- Conditions
- Schizophrenia
- Interventions
- Iclepertin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Anaheim, California • Culver City, California • Los Angeles, California + 19 more
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate Liposome
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 128 more
- Conditions
- Von Willebrand Factor Deficiency
- Interventions
- Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
- Conditions
- Stress, Physiological, Infertility, Stress, Psychological
- Interventions
- Not listed
- Lead sponsor
- Inception Fertility Research Institute, LLC
- Industry
- Eligibility
- 25 Years to 40 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 43
- States / cities
- Boca Raton, Florida • Celebration, Florida • Cooper City, Florida + 34 more
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer
- Interventions
- Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Neuromuscular Blockade
- Interventions
- Sugammadex, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Gastroesophageal Reflux
- Interventions
- pantoprazole
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 1 Day to 28 Days
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Loma Linda, California • Oakland, California + 42 more
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Positron Emission Tomography, Sodium Fluoride F-18
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia